IQVIA Holdings Inc. (NYSE: IQV) announced that its subsidiary IQVIA Inc. priced an offering of €950 million in senior notes due 2033. The notes will carry an interest rate of 4.625% per annum with semi-annual payments on June 15 and December 15 each year, beginning December 15, 2026.

The notes will mature on June 15, 2033, unless earlier repurchased or redeemed. The issuance is expected to occur on or about June 11, 2026, subject to customary closing conditions.

IQVIA stated the proceeds will be used to refinance certain existing debt and pay fees and expenses related to the offering. The notes are being offered to qualified institutional buyers in the United States under Rule 144A and to non-U.S. investors outside the United States pursuant to Regulation S under the Securities Act.

The notes have not been registered under the Securities Act of 1933 and are being offered only through a private offering memorandum. IQVIA is a clinical research services and healthcare intelligence provider to the life sciences and healthcare industries, with approximately 93,000 employees in over 100 countries.